Loading stock data…
RDHL
$1.08-0.00 (-0.46%)
Market ClosedLast close May 1
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RedHill Biopharma Ltd. in the Healthcare sector is trading at $1.08. The stock is currently near its 52-week low of $0.71, remaining 13.9% below its 200-day moving average. Technical signals show overbought RSI of 89 and bullish MACD crossover, explaining why RDHL maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 89) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.08
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
4.92
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
211.08%
Volume
Today's trading volume
17,812